RT Journal Article
SR Electronic
T1 AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.26.20154724
DO 10.1101/2020.07.26.20154724
A1 Ivashchenko, Andrey A.
A1 Dmitriev, Kirill A.
A1 Vostokova, Natalia V.
A1 Azarova, Valeria N.
A1 Blinow, Andrew A.
A1 Egorova, Alina N.
A1 Gordeev, Ivan G.
A1 Ilin, Alexey P.
A1 Karapetian, Ruben N.
A1 Kravchenko, Dmitry V.
A1 Lomakin, Nikita V.
A1 Merkulova, Elena A.
A1 Papazova, Natalia A.
A1 Pavlikova, Elena P.
A1 Savchuk, Nikolay P.
A1 Simakina, Elena N.
A1 Sitdekov, Tagir A.
A1 Smolyarchuk, Elena A.
A1 Tikhomolova, Elena G.
A1 Yakubova, Elena V.
A1 Ivachtchenko, Alexandre V.
YR 2020
UL http://medrxiv.org/content/early/2020/08/05/2020.07.26.20154724.abstract
AB In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04434248Funding StatementThis project is supported financially by the Russian Direct Investment Fund, the Ministry of Industry and Trade of the Russian Federation and The Skolkovo Innovation Center. Development, manufacturing, and marketing of the investigational product used in this study was provided by ChemRar group of companies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ministry of Health of the Russian FederationAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A